MVI envisions a world where country leaders and their partners have the tools, evidence, financial capacity, human resources and political will to control, eliminate and eventually eradicate malaria.

To this end, MVI supports two pathways: one is to improve current vaccines, working to optimize the use of RTS,S/AS01 and continue learning from its development, and the other is to develop new vaccines and monoclonal antibodies (mAbs). We are targeting development of next-generation malaria vaccines and mAbs that can be used in the context of comprehensive malaria control programs, with the aim of accelerating parasite elimination. We also work closely with PATH teams and partners working to implement first-generation malaria vaccines and other malaria interventions, which guides the development of new products to ensure they meet the needs of communities.

Looking to the next several years, MVI will focus on three key areas of work:

• First-generation vaccines, including optimizing the use of and learning from the world's first malaria vaccine, RTS,S, and other similar circumsporozoite-based vaccines.
• Next-generation vaccines targeting various stages of the Plasmodium parasite's lifecycle to develop candidates with higher efficacy and improved durability.
• Monoclonal antibodies targeting the circumsporozoite protein as well as others to block transmission of the parasite.